Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
about
CCR5 monoclonal antibodies for HIV-1 therapyInhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agentMaraviroc: a review of its use in HIV infection and beyondCCR5 Targeted Cell Therapy for HIV and Prevention of Viral EscapeClinical significance of HIV-1 coreceptor usage.Access denied? The status of co-receptor inhibition to counter HIV entryStructural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usageAccelerated immunodeficiency by anti-CCR5 treatment in HIV infectionThe evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time--an ultra-deep approachMaraviroc: the evidence for its potential in the management of HIVSusceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitorsParameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on MaravirocHIV-1 drug resistance and resistance testing.Defining the fitness of HIV-1 isolates with dual/mixed co-receptor usageAppreciating HIV type 1 diversity: subtype differences in Env.Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes.Prospects for treatment of latent HIV.Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispeciesUnderstanding the HIV coreceptor switch from a dynamical perspective.Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.Different tempo and anatomic location of dual-tropic and X4 virus emergence in a model of R5 simian-human immunodeficiency virus infection.Characterization of human immunodeficiency virus type 1 populations containing CXCR4-using variants from recently infected individualsAnti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.HIV type 1 from a patient with baseline resistance to CCR5 antagonists uses drug-bound receptor for entry.Loss of asparagine-linked glycosylation sites in variable region 5 of human immunodeficiency virus type 1 envelope is associated with resistance to CD4 antibody ibalizumab.Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.Resistance to the CCR5 inhibitor 5P12-RANTES requires a difficult evolution from CCR5 to CXCR4 coreceptor use.Switching of inferred tropism caused by HIV during interruption of antiretroviral therapy.Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infectionHIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cellsThree-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients.Distinct molecular pathways to X4 tropism for a V3-truncated human immunodeficiency virus type 1 lead to differential coreceptor interactions and sensitivity to a CXCR4 antagonist.Short communication: antiretroviral therapy resistance mutations present in the HIV type 1 subtype C pol and env regions from therapy-naive patients in ZambiaVariation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II.HIV-1 antiretroviral resistance: scientific principles and clinical applicationsAn expanded model of HIV cell entry phenotype based on multi-parameter single-cell data.The role of genetic variants of Stromal cell-Derived Factor 1 in pediatric HIV-1 infection and disease progression.
P2860
Q22242739-FEEC6C4B-6578-4533-974C-01A36F26C24FQ24656023-458522F2-D588-4346-989C-B6FDA71296AAQ26778504-CD7D1765-70ED-4D45-A6D5-B1062300EA65Q26801498-9B5D50FA-D84B-4CFC-8A88-3935336C1CF6Q27691426-B2701E45-2D1F-4A64-8029-8901DBEFF020Q28300187-BC162686-A103-4A86-8F80-5ACE557439BBQ28469177-A1327377-B8B6-41BE-A2A7-A370D9AFBC08Q28475890-99429527-1942-48AA-AD29-EAECB88BF1CAQ28476558-34157060-14ED-4AEE-8BAF-0ADCD6547FAFQ28476655-5641B353-D8CE-4945-9488-D7911929D10EQ28477409-01E2C270-C64C-4F21-B4EB-ED550B1202D7Q28547216-E1711B86-1245-428D-B8E2-EFB6BC6817A0Q30245693-3F929562-1749-4D7C-99B0-54B534F93F51Q30278577-A29047BA-8416-4FC8-854C-B9D9DE7008AEQ30375834-47A28B3A-D0F5-45A7-8A47-388D2D6D0E15Q30378764-364AC98D-C988-4441-B1FF-20EFE18D5A48Q30421453-B45777C4-4AC8-404F-88F0-7617165617F8Q30424413-87B3A961-C51A-4301-814E-5DFA82391D54Q30834495-B4AF831A-BAD2-4218-90A9-3B196A404C04Q30931832-57DC67E5-49DB-4080-A446-BD5978EA10B3Q33455862-816FBC53-FBB8-4FB1-9639-59FDE5500290Q33558676-C77BBAAD-8ADA-4B9E-8BBE-5786B9CE88A8Q33685141-04C8E10B-DF7A-46AC-9783-0215BDF49AE0Q33798442-B605D097-7550-4A54-9A85-F26E0E84B013Q33807529-6ED195FF-303A-4D3C-9F84-EC1D2CCA7FA0Q33810849-A6314641-D4D0-4EC4-B220-3BDBD32779CAQ33886716-E252D22F-A800-40D2-A242-5376C55B96A8Q33951977-096A73E8-1A1E-4F38-88B6-A363D57B65F9Q33961704-6C3177C9-C859-4256-A13E-81DF64F60701Q33963459-3068AF72-F9E0-4B58-A2FB-0F221343B1F8Q33973857-D53FF3E4-BA60-48DF-90DB-57E395303DCEQ33990552-25623F5E-BD51-449E-BC1A-DDDF4F6129F4Q34051325-36CBBBCB-F165-4C3C-942D-D04959BEDA5BQ34055508-495438F0-2C38-417B-A33E-0274CCAF7D2AQ34100228-9FFF9FC8-8252-4FFE-B1E7-14BE5BCBE2CEQ34170655-B9C26EED-779E-4246-AA57-0149977153E2Q34207464-6BD23020-1B02-4CBF-AED2-C3149743D0DDQ34280466-5D6D4E89-3B13-4688-946C-FD987872453AQ34351378-2E1F7420-E683-4A05-8290-71D8E6EBA225Q34409877-4C7340D8-F23D-443C-8805-866DC4611123
P2860
Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Emergence of CXCR4-using human ...... t CXCR4-using virus reservoir.
@en
Emergence of CXCR4-using human immunodeficiency virus type 1
@nl
type
label
Emergence of CXCR4-using human ...... t CXCR4-using virus reservoir.
@en
Emergence of CXCR4-using human immunodeficiency virus type 1
@nl
prefLabel
Emergence of CXCR4-using human ...... t CXCR4-using virus reservoir.
@en
Emergence of CXCR4-using human immunodeficiency virus type 1
@nl
P2093
P2860
P1433
P1476
Emergence of CXCR4-using human ...... t CXCR4-using virus reservoir.
@en
P2093
Anton L Pozniak
Elna van der Ryst
Ian T James
Jeannette Whitcomb
Manos Perros
Marilyn Lewis
Mike Westby
Mike Youle
Tim M Jenkins
P2860
P304
P356
10.1128/JVI.80.10.4909-4920.2006
P407
P577
2006-05-01T00:00:00Z